Wang et al. found that the transcription factor C/EBPβ contributes to increased H3K79 methylation modifications through recruitment of DOT1L, thereby reducing the efficacy of ovarian cancer chemotherapy (Wang et al., 2019). This evidence concerns the gene DOT1L and ovarian cancer.